Zentiva (SCD) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024, reached RON 825.0 million, up 20.5% year-over-year, with net profit rising to RON 202.0 million from RON 123.9 million.

• Operating profit increased to RON 198.2 million from RON 112.5 million year-over-year, driven by higher sales and improved operational efficiency.

• The company operates a single segment focused on the production of medicines, with most sales in Romania and significant external sales to the Czech Republic.

• Market capitalization as of September 30, 2024, was RON 2.83 billion, with a share price of RON 4.06.

Financial highlights

• Revenue grew to RON 825.0 million from RON 684.5 million year-over-year; net earnings per share increased to RON 0.29 from RON 0.18.

• Operating profit rose to RON 198.2 million, and profit before tax reached RON 229.1 million, both up significantly year-over-year.

• Cash and cash equivalents stood at RON 23.6 million, with a net cash inflow from operating activities of RON 56.3 million for the period.

• Total assets increased to RON 1.73 billion from RON 1.50 billion at year-end 2023; equity rose to RON 1.39 billion.

• No long-term debt; unused credit facility of RON 10 million available.

Outlook and guidance

• Management expects continued positive cash flows, sales growth, and profitability from direct distribution of generic medicines in Romania and imports from group entities.

• The going concern assumption is considered reasonable based on current forecasts and financial position.